SC
RCUS icon

SummitTX Capital’s Arcus Biosciences RCUS Stock Holding History

SummitTX Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$739K Buy
34,219
+5,076
+17% +$110K 0.02% 505
2025
Q4 		$694K Buy
29,143
+11,589
+66% +$236K 0.02% 478
2025
Q3 		$239K Sell
17,554
-11,070
-39% -$115K 0.01% 675
2025
Q2 		$233K Sell
28,624
-82,266
-74% -$703K 0.01% 666
2025
Q1 		$870K Buy
+110,890
New +$1.29M 0.04% 434

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SummitTX Capital's RCUS Position: Q1 2026 in Review

SummitTX Capital increased its Arcus Biosciences (RCUS) stake by 17% in Q1 2026, buying an estimated $110K and bringing the position to 34,219 shares worth $739K. The position accounts for 0.02% of the portfolio, ranked #505.

SummitTX Capital first reported a position in RCUS in Q1 2025 and has held it in 5 quarters since. The position peaked at $870K in Q1 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • SummitTX Capital held 34,219 shares of Arcus Biosciences worth $739K as of Q1 2026.
  • SummitTX Capital bought 5,076 Arcus Biosciences shares in Q1 2026, an estimated $110K.
  • Arcus Biosciences made up 0.02% of SummitTX Capital's portfolio in Q1 2026, its #505 holding.
  • SummitTX Capital first reported a position in Arcus Biosciences in Q1 2025 and has held it in 5 quarters since.
  • SummitTX Capital's Arcus Biosciences position peaked at $870K in Q1 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.